Evgen Pharma PLC Issue of Equity, PDMR Shareholding and TVR (5486Y)

TIDMEVG

RNS Number : 5486Y

Evgen Pharma PLC

06 March 2017

 
 For immediate release   6 March 2017

Evgen Pharma plc

("Evgen Pharma" or "the Company")

Issue of Equity, Director/PDMR Shareholding and Total Voting Rights

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that it has received notices to exercise options over 129,729 ordinary shares in the Company including a notice from David Howat, a Person Discharging Managerial Responsibility.

The options were granted under The Evgen Pharma plc Long Term Incentive Plan and have an exercise price of nil pence per share. Accordingly, the Company has issued and allotted 129,729 new ordinary shares of 0.25 pence each ("New Ordinary Shares"). The New Ordinary Shares rank pari passu with the Company's existing issued ordinary shares. Application has been made to admit the New Ordinary Shares to trading on AIM and dealings in these shares are expected to commence at 8.00 a.m. on 10 March 2017.

There are no shares held in treasury, therefore following the admission of the New Ordinary Shares the total number of voting rights in the Company will be 73,272,591. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest under the Disclosure and Transparency Rules.

Enquiries:

 
 Evgen Pharma plc                              c/o +44 (0) 20 
  Dr Stephen Franklin, CEO                          7466 5000 
  www.evgen.com 
 
 Buchanan 
  Mark Court, Sophie Cowles, Stephanie             +44 (0) 20 
  Watson                                            7466 5000 
 
 Northland Capital Partners Limited 
  Matthew Johnson, Gerry Beaney, Margarita 
  Mitropoulou (Corporate Finance) 
  John Howes and Rob Rees (Corporate               +44 (0) 20 
  Broking)                                          3861 6625

Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. It is also carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. The Company's core technology is Sulforadex(R), a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

Evgen Pharma commenced operations in January 2008 and has its registered office at the Liverpool Science Park and its headquarters in Wilmslow, Cheshire, UK. Evgen Pharma joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.

For further information please visit: www.evgen.com

For a recent analyst research note on Evgen Pharma, please visit:

http://www.hardmanandco.com/docs/default-source/company-docs/evgen-pharma-documents/29.11.16-harnessing-the-clinical-potential-of-sulforaphane.pdf

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCUGUGPWUPMPGA

(END) Dow Jones Newswires

March 06, 2017 02:00 ET (07:00 GMT)

Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Giu 2024 a Lug 2024